Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Summary

Teva Pharmaceutical Industries and Polpharma Biologics announced a global licensing agreement granting Teva exclusive commercialization rights for Polpharma's proposed ocrelizumab biosimilar candidate for multiple sclerosis upon regulatory approval.